Clinical Trial Update: Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE) [Phase 2]

View source ↗

Summary

Phase 2 GENEVIEVE trial comparing cabazitaxel to weekly paclitaxel as neoadjuvant therapy in specific breast cancer subtypes to assess efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Luminal Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Cabazitaxel (cabazitaxel)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: GBG Forschungs GmbH | Conditions: Primary Breast Cancer | Phase 2 | Status: COMPLETED